Preclinical studies in melanoma, glioblastoma, and ovarian cancer have shown that low levels of p16 and the high expression of cyclin D/Retinoblastoma (Rb) proteins may be thought as biomarkers for the prediction of sensitivity to the CDK4/6i [20,21,22]. The gene discussed is RB1; the disease is melanoma.